Display options
Share it on

Nouv Rev Fr Hematol. 1987;29(5):289-93.

[Clinical and biological evaluation of the preventive role of anti-cytomegalovirus specific immunoglobulins in bone marrow grafts. Randomized study of 60 patients].

Nouvelle revue francaise d'hematologie

[Article in French]
P Bordigoni, C Janot, J P Aymard, F Witz, M C Bené, B Legras, F Schoonemann, D Olive, F Streiff

Affiliations

  1. Unité de greffe médullaire, Hôpital d'Enfants, Centre Hospitalier Universitaire de Nancy, France.

PMID: 2830588

Abstract

The effects of i.v. cytomegalovirus (CMV) immunoglobulin given for prophylaxis of CMV infections in recipients of allogeneic and autologous marrow transplants were evaluated in a randomized trial: 60 patients were randomly assigned to receive (30 patients) or not to receive (30 patients) CMV immunoglobulin for a period of 90 days after transplantation. As to the allografted patients, the cumulative incidence of asymptomatic and symptomatic CMV infections was significantly reduced in the CMV immunoglobulin-treated group as compared to the control group (56.5% versus 92.9%, P less than 0.05). No other statistically significant effect of CMV immunoglobulin could be found. In particular, the incidence of symptomatic CMV infections (including interstitial pneumonia), the mean delay of post-transplant viraemia and haematopoietic recovery were similar in the control and CMV immunoglobulin-treated groups. We conclude that prophylactic CMV immunoglobulin administration, as designed in our study, is no more than marginally effective and cannot be recommended without additional trials.

Similar articles

Substances

MeSH terms

Publication Types

LinkOut - more resources